Trial Profile
Phase II trial of Hsp-E7 (SGN-00101 [verpasep caltespen]) in women with high grade cervical dysplasia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2006
Price :
$35
*
At a glance
- Drugs Verpasep caltespen (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- 20 Feb 2006 New trial record.